NervGen Pharma Corp. (NGEN : NASDAQ)
Common Stock
Follow NGEN
NGEN
NervGen Pharma Corp.
Performance
1 Day
+1.05%
1 Week
+17.79%
1 Month
+24.68%
YTD
-12.33%
The Saturday TSX Wrap · free, every saturday morning. The week on the TSX, in five minutes.
Key Statistics
Market Cap
$202.14M
52W High
$6.30
52W Low
$1.28
P/E Ratio
-
50 Day MA
$1.74
200 Day MA
$2.67
Beta
0.78
Dividend Yield
-
Performance history
NGEN returns since 2026
NervGen Pharma Corp. has traded since Jun 2026 in our data. Its deepest fall was −43.5% (Aug 2026 to Nov 2026).
1 year / yr
—
3 years / yr
—
5 years / yr
—
10 years / yr
—
Calendar-year returns
- 2026*−12.3%
* Partial year (first year of data, or year to date).
$10,000 invested in NGEN
- 2026 (start of our data)$8,767
- All-time high in our data
- $2 on Aug 27, 2026 · now −17.8%
Total-return basis using adjusted daily closes from the Toronto Stock Exchange and TSX Venture (dividends and splits folded in), Jun 2026 to Nov 2026. Past returns do not predict future ones.
Awesome Portfolio™
Looking past NGEN? Our 10 best Canadian stocks, in one list.
14.8% a year since 2017 against 9.7% for the S&P/TSX Composite (+5.0 points a year). Reviewed every month.
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 11/19/2026 | $1.89 | $1.99 | $1.85 | $1.92 | $1.92 | 653,270 |
| 11/18/2026 | $1.99 | $2.08 | $1.83 | $1.90 | $1.90 | 1,130,894 |
| 11/17/2026 | $1.81 | $2.08 | $1.80 | $1.96 | $1.96 | 1,685,955 |
| 11/16/2026 | $1.85 | $2.08 | $1.75 | $1.82 | $1.82 | 1,618,243 |
| 11/13/2026 | $1.68 | $1.94 | $1.62 | $1.88 | $1.88 | 1,992,100 |
| 11/12/2026 | $1.38 | $1.63 | $1.36 | $1.63 | $1.63 | 2,555,134 |
| 11/11/2026 | $1.35 | $1.39 | $1.33 | $1.35 | $1.35 | 233,947 |
| 11/10/2026 | $1.39 | $1.41 | $1.32 | $1.33 | $1.33 | 263,745 |
| 11/9/2026 | $1.35 | $1.41 | $1.31 | $1.40 | $1.40 | 349,301 |
| 11/6/2026 | $1.30 | $1.34 | $1.29 | $1.33 | $1.33 | 447,800 |
Analyst Price Targets
Based on 6 analysts covering NGEN · as of Nov 9, 2026
Wall Street analysts forecast NGEN stock price to rise 420.8% over the next 12 months.
Consensus
Strong Buy4.67 / 5.00
Avg. Target
US$10.00
+420.8% Upside
Current Price
US$1.92
Last close
Analyst Breakdown (6 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on NGEN's historical volatility
30-Day Vol
87.2%
Annualized
90-Day Vol
66.6%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
US$1.61
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$1.81 | US$1.34 – US$2.44 |
| 60 trading days | US$1.70 | US$1.11 – US$2.61 |
| 90 trading days | US$1.61 | US$0.95 – US$2.70 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About NervGen Pharma Corp.
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-32.54M
- Profit Margin
- 0.00%
- ROE (TTM)
- -96.84%
- EPS (Diluted)
- -0.57
- Book Value
- 0.31
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Free newsletter
The Saturday TSX Wrap
The week on the TSX, in five minutes
- The biggest gainers and losers, and why they moved
- Sector and momentum moves at a glance
- The Canadian market stories you missed
Explore More
Common Questions About NGEN.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| SEAT | Vivid Seats Inc | $2.09 | +63.28% |
| MRKR | Marker Therapeutics Inc | $1.32 | +54.71% |
| ELOG | Eastern International Ltd. | $1.45 | +46.46% |
| BAER | Bridger Aerospace Group Holdings, Inc. Common Stock | $0.31 | +45.64% |
| ZKIN | ZK International Group Co Ltd | $1.65 | +32.00% |
| FLD | Fold Holdings, Inc. Class A Common Stock | $0.29 | +27.19% |
| FISN | Deep Fission, Inc. Common Stock | $3.41 | +25.83% |
| ZEO | Zeo Energy Corp. | $0.29 | +24.09% |
Free with a Wealth Awesome account
Keep analysing NGEN, free
- Every WA Score, ranking and table
- Insider track records and SEDI filings
- Earnings history and analyst targets for every stock
Email only, no password, no card. Already a member? Use the same button to sign in.
